Treace Medical Concepts, Inc. (TMCI)

NASDAQ: TMCI · IEX Real-Time Price · USD
20.29
+0.38 (1.91%)
At close: Aug 15, 2022 4:00 PM
20.63
+0.34 (1.68%)
After-hours: Aug 15, 2022 5:54 PM EDT
1.91%
Market Cap 1.12B
Revenue (ttm) 114.07M
Net Income (ttm) -39.31M
Shares Out 55.40M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 308,262
Open 19.70
Previous Close 19.91
Day's Range 19.49 - 20.56
52-Week Range 12.48 - 31.02
Beta n/a
Analysts Buy
Price Target 26.01 (+28.2%)
Earnings Date Aug 9, 2022

About TMCI

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, interc... [Read more...]

Industry Medical Devices
IPO Date Apr 23, 2021
Employees 248
Stock Exchange NASDAQ
Ticker Symbol TMCI
Full Company Profile

Financial Performance

In 2021, TMCI's revenue was $94.42 million, an increase of 64.59% compared to the previous year's $57.37 million. Losses were -$20.55 million, 460.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for TMCI stock is "Buy." The 12-month stock price forecast is 26.01, which is an increase of 28.19% from the latest price.

Price Target
$26.01
(28.19% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of -9.52% and 4.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Treace Announces Full Commercial Release of New Technologies for Bunion and Related Midfoot Surgery

PONTE VEDRA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical ...

Treace to Host Surgeon Advisor Event on September 20, 2022

PONTE VEDRA, Fla., July 25, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hall...

Treace to Report Second Quarter 2022 Financial Results on August 9, 2022

PONTE VEDRA, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hall...

Treace Medical Concepts (TMCI) Moves 8.2% Higher: Will This Strength Last?

Treace Medical Concepts (TMCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price ...

Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 20% and 10.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Treace Medical Concepts Reports First Quarter 2022 Financial Results

PONTE VEDRA, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical t...

Treace Announces Peer-Reviewed Publication of ALIGN3D™ Multicenter Prospective Clinical Data

PONTE VEDRA, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux ...

Treace Secures Up to $150 Million in Debt Financing

PONTE VEDRA, Fla., May 02, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a medical technology company driving a fundamental shift in the surgical tre...

Treace to Report First Quarter 2022 Financial Results on May 5, 2022

PONTE VEDRA, Fla., April 14, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a paradigm shift in the surgical treatment of Hallux...

Treace Files Patent Infringement Suit To Protect Lapiplasty® Bunion Technology

PONTE VEDRA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a medical technology company driving a fundamental shift in the surgical t...

Treace Medical Concepts Reports Fourth Quarter and Full Year 2021 Financial Results

PONTE VEDRA, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a paradigm shift in the surgical tr...

Treace Announces Updated ALIGN3D™ Data at the 2022 ACFAS Scientific Conference

PONTE VEDRA, Fla., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgic...

Treace Highlights New Product Innovations at the 2022 ACFAS Scientific Conference

PONTE VEDRA, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgic...

Treace to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

PONTE VEDRA, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surg...

Treace to Announce Latest ALIGN3D™ Data at the 2022 ACFAS Scientific Conference

PONTE VEDRA, Fla., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgic...

Treace Announces Grant of U.S. Patent on Instrumented Bunion Correction

PONTE VEDRA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm sh...

Treace to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

PONTE VEDRA, Fla., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgic...

Treace Announces Grant of U.S. Patent and Allowance of U.S. Patent Application on Bone Positioner Technology for Buni...

PONTE VEDRA, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm sh...

Treace Announces Participation in the Stifel 2021 Virtual Healthcare Conference

PONTE VEDRA, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgic...

Treace Announces Grant of Additional U.S. Patent on Instrumented Bunion Correction

PONTE VEDRA, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm sh...

Treace to Report Third Quarter 2021 Financial Results on November 4, 2021

PONTE VEDRA, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surg...

Treace Announces New ALIGN3D™ Data at the 2021 AOFAS Annual Meeting

PONTE VEDRA, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgi...

Treace Announces Launch of Adductoplasty™ Instrumented Midfoot Correction System

PONTE VEDRA, Fla., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgi...

Treace Announces Participation in the Morgan Stanley 19th Annual Global Healthcare Conference

PONTE VEDRA, Fla., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgi...